Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1996 May;14(2):317-35.
doi: 10.1016/S0733-8619(05)70259-0.

Epidemiology of Parkinson's disease

Affiliations
Review

Epidemiology of Parkinson's disease

C M Tanner et al. Neurol Clin. 1996 May.

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Parkinson's disease age-specific prevalence.

References

    1. Acosta J., Calderon E., Obeso J.A. Prevalence of Parkinson's disease and essential tremor in a village of south Spain [abstract] Neurology. 1989;39(suppl 1):181.
    1. Agundez J.A., Jimenez-Jimenez F.J., Luengo A. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther. 1995;57:291–298. - PubMed
    1. Ansher S.S., Cadet J.L., Jakoby W.B. Role of N-methyltransferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines present in the environment. Biochem Pharmacol. 1986;35:3359–3363. - PubMed
    1. Aquilonius S.M., Hartvig P. A Swedish county with unexpectedly high utilization of anti-parkinsonian drugs. Acta Neurol Scand. 1986;74:379–382. - PubMed
    1. Armstrong M., Daly A.K., Chalerton S. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 1992;339:1017–1018. - PubMed

MeSH terms

Substances